{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T18:50:22Z","timestamp":1793299822612,"version":"4.5.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Crit Care"],"published-print":{"date-parts":[[2015,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Vital drugs may be degraded or sequestered in extracorporeal membrane oxygenation (ECMO) circuits, with lipophilic drugs considered to be particularly vulnerable. However, the circuit effects on protein-bound drugs have not been fully elucidated. The aim of this experimental study was to investigate the influence of plasma protein binding on drug disposition in<jats:italic>ex vivo<\/jats:italic>ECMO circuits.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Four identical ECMO circuits comprising centrifugal pumps and polymethylpentene oxygenators and were used. The circuits were primed with crystalloid, albumin and fresh human whole blood and maintained at a physiological pH and temperature for 24\u00a0hours. After baseline sampling, known quantities of study drugs (ceftriaxone, ciprofloxacin, linezolid, fluconazole, caspofungin and thiopentone) were injected into the circuit to achieve therapeutic concentrations. Equivalent doses of these drugs were also injected into four polypropylene jars containing fresh human whole blood for drug stability testing. Serial blood samples were collected from the controls and the ECMO circuits over 24\u00a0hours, and the concentrations of the study drugs were quantified using validated chromatographic assays. A regression model was constructed to examine the relationship between circuit drug recovery as the dependent variable and protein binding and partition coefficient (a measure of lipophilicity) as explanatory variables.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Four hundred eighty samples were analysed. There was no significant loss of any study drugs in the controls over 24\u00a0hours. The average drug recoveries from the ECMO circuits at 24\u00a0hours were as follows: ciprofloxacin 96%, linezolid 91%, fluconazole 91%, ceftriaxone 80%, caspofungin 56% and thiopentone 12%. There was a significant reduction of ceftriaxone (<jats:italic>P<\/jats:italic>= 0.01), caspofungin (<jats:italic>P<\/jats:italic>= 0.01) and thiopentone (<jats:italic>P<\/jats:italic>= 0.008) concentrations in the ECMO circuit at 24\u00a0hours. Both protein binding and partition coefficient were highly significant, with the model possessing a high coefficient of determination (<jats:italic>R<\/jats:italic><jats:sup>2<\/jats:sup>\u2009=\u20090.88,<jats:italic>P<\/jats:italic>&lt;0.001).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Recovery of the highly protein-bound drugs ceftriaxone, caspofungin and thiopentone was significantly lower in the ECMO circuits at 24\u00a0hours. For drugs with similar lipophilicity, the extent of protein binding may determine circuit drug loss. Future clinical population pharmacokinetic studies should initially be focused on drugs with greater lipophilicity and protein binding, and therapeutic drug monitoring should be strongly considered with the use of such drugs.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s13054-015-0891-z","type":"journal-article","created":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T08:33:41Z","timestamp":1427877221000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":231,"title":["Protein-bound drugs are prone to sequestration in the extracorporeal membrane oxygenation circuit: results from an ex vivo study"],"prefix":"10.1186","volume":"19","author":[{"given":"Kiran","family":"Shekar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason A","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles I","family":"Mcdonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sussan","family":"Ghassabian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Anstey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven C","family":"Wallis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel V","family":"Mullany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoke L","family":"Fung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F","family":"Fraser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,12,1]]},"reference":[{"key":"891_CR1","first-page":"534","volume":"76","author":"RH Bartlett","year":"2010","unstructured":"Bartlett RH, Gattinoni L. Current status of extracorporeal life support (ECMO) for cardiopulmonary failure. Minerva Anestesiol. 2010;76:534\u201340.","journal-title":"Minerva Anestesiol"},{"key":"891_CR2","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1186\/cc13865","volume":"18","author":"K Shekar","year":"2014","unstructured":"Shekar K, Mullany DV, Thomson B, Ziegenfuss M, Platts DG, Fraser JF. Extracorporeal life support devices and strategies for management of acute cardiorespiratory failure in adult patients: a comprehensive review. Crit Care. 2014;18:219.","journal-title":"Crit Care"},{"key":"891_CR3","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1016\/j.jacc.2014.03.046","volume":"63","author":"D Abrams","year":"2014","unstructured":"Abrams D, Combes A, Brodie D. Extracorporeal membrane oxygenation in cardiopulmonary disease in adults. J Am Coll Cardiol. 2014;63:2769\u201378.","journal-title":"J Am Coll Cardiol"},{"key":"891_CR4","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1007\/s00134-012-2785-8","volume":"39","author":"M Schmidt","year":"2013","unstructured":"Schmidt M, Tachon G, Devilliers C, Muller G, Hekimian G, Br\u00e9chot N, et al. Blood oxygenation and decarboxylation determinants during venovenous ECMO for respiratory failure in adults. Intensive Care Med. 2013;39:838\u201346.","journal-title":"Intensive Care Med"},{"key":"891_CR5","doi-asserted-by":"publisher","first-page":"R194","DOI":"10.1186\/cc11679","volume":"16","author":"K Shekar","year":"2012","unstructured":"Shekar K, Roberts JA, McDonald CI, Fisquet S, Barnett AG, Mullany DV, et al. Sequestration of drugs in the circuit may lead to therapeutic failure during extracorporeal membrane oxygenation. Crit Care. 2012;16:R194.","journal-title":"Crit Care"},{"key":"891_CR6","doi-asserted-by":"crossref","unstructured":"Shekar K, Fraser JF, Smith MT, Roberts JA. Pharmacokinetic changes in patients receiving extracorporeal membrane oxygenation. J Crit Care. 2012;27:741.e9\u201318.","DOI":"10.1016\/j.jcrc.2012.02.013"},{"key":"891_CR7","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1471-2253-13-7","volume":"13","author":"K Shekar","year":"2013","unstructured":"Shekar K, Roberts JA, Smith MT, Fung YL, Fraser JF. The ECMO PK Project: an incremental research approach to advance understanding of the pharmacokinetic alterations and improve patient outcomes during extracorporeal membrane oxygenation. BMC Anesthesiol. 2013;13:7.","journal-title":"BMC Anesthesiol"},{"key":"891_CR8","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1023\/A:1008741731244","volume":"19","author":"B Testa","year":"2000","unstructured":"Testa B, Crivori P, Reist M, Carrupt PA. The influence of lipophilicity on the pharmacokinetic behavior of drugs: concepts and examples. Perspect Drug Discov Des. 2000;19:179\u2013211.","journal-title":"Perspect Drug Discov Des"},{"key":"891_CR9","volume-title":"Basic pharmacokinetics and pharmacodynamics: an integrated textbook and computer simulations","author":"S Rosenbaum","year":"2011","unstructured":"Rosenbaum S. Basic pharmacokinetics and pharmacodynamics: an integrated textbook and computer simulations. Hoboken, NJ: John Wiley & Sons; 2011. ISBN 9780470569061."},{"key":"891_CR10","doi-asserted-by":"publisher","first-page":"403","DOI":"10.2165\/00003088-200342050-00001","volume":"42","author":"ML Buck","year":"2003","unstructured":"Buck ML. Pharmacokinetic changes during extracorporeal membrane oxygenation: implications for drug therapy of neonates. Clin Pharmacokinet. 2003;42:403\u201317.","journal-title":"Clin Pharmacokinet"},{"key":"891_CR11","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1007\/s00134-010-2041-z","volume":"36","author":"ED Wildschut","year":"2010","unstructured":"Wildschut ED, Ahsman MJ, Allegaert K, Mathot RA, Tibboel D. Determinants of drug absorption in different ECMO circuits. Intensive Care Med. 2010;36:2109\u201316.","journal-title":"Intensive Care Med"},{"key":"891_CR12","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1191\/0267659105pf827oa","volume":"20","author":"V Bhatt-Meht","year":"2005","unstructured":"Bhatt-Meht V, Annich G. Sedative clearance during extracorporeal membrane oxygenation. Perfusion. 2005;20:309\u201315.","journal-title":"Perfusion"},{"key":"891_CR13","first-page":"105","volume":"14","author":"K Shekar","year":"2012","unstructured":"Shekar K, Fung YL, Diab S, Mullany DV, McDonald CI, Dunster KR, et al. Development of simulated and ovine models of extracorporeal life support to improve understanding of circuit-host interactions. Crit Care Resusc. 2012;14:105\u201311.","journal-title":"Crit Care Resusc"},{"key":"891_CR14","unstructured":"Center for Drug Evaluation and Research, US Food and Drug Administration. Guidance for industry: bioanalytical method validation. 2001. US Department of Health and Human Services, Rockville, MD. Available from: http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM070107.pdf. Accessed 6 Apr 2015."},{"key":"891_CR15","doi-asserted-by":"publisher","first-page":"D901","DOI":"10.1093\/nar\/gkm958","volume":"36","author":"DS Wishart","year":"2008","unstructured":"Wishart DS, Knox C, Guo AC, Cheng D, Shrivastava S, Tzur D, et al. DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008;36:D901\u20136.","journal-title":"Nucleic Acids Res"},{"key":"891_CR16","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1097\/CCM.0b013e3181961bff","volume":"37","author":"JA Roberts","year":"2009","unstructured":"Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med. 2009;37:840\u201351. quiz 859.","journal-title":"Crit Care Med"},{"key":"891_CR17","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2165\/11539220-000000000-00000","volume":"50","author":"M Ulldemolins","year":"2011","unstructured":"Ulldemolins M, Roberts JA, Rello J, Paterson DL, Lipman J. The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients. Clin Pharmacokinet. 2011;50:99\u2013110.","journal-title":"Clin Pharmacokinet"},{"key":"891_CR18","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1093\/jac\/dkq044","volume":"65","author":"K Berthoin","year":"2010","unstructured":"Berthoin K, Le Duff CS, Marchand-Brynaert J, Carryn S, Tulkens PM. Stability of meropenem and doripenem solutions for administration by continuous infusion. J Antimicrob Chemother. 2010;65:1073\u20135.","journal-title":"J Antimicrob Chemother"},{"key":"891_CR19","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1093\/bja\/85.4.599","volume":"85","author":"JP Nicholson","year":"2000","unstructured":"Nicholson JP, Wolmarans MR, Park GR. The role of albumin in critical illness. Br J Anaesth. 2000;85:599\u2013610.","journal-title":"Br J Anaesth"},{"key":"891_CR20","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1007\/s00134-007-0606-2","volume":"33","author":"NM Mehta","year":"2007","unstructured":"Mehta NM, Halwick DR, Dodson BL, Thompson JE, Arnold JH. Potential drug sequestration during extracorporeal membrane oxygenation: results from an ex vivo experiment. Intensive Care Med. 2007;33:1018\u201324.","journal-title":"Intensive Care Med"},{"key":"891_CR21","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1051\/ject\/200739234","volume":"39","author":"TJ Preston","year":"2007","unstructured":"Preston TJ, Hodge AB, Riley JB, Leib-Sargel C, Nicol KK. In vitro drug adsorption and plasma free hemoglobin levels associated with hollow fiber oxygenators in the extracorporeal life support (ECLS) circuit. J Extra Corpor Technol. 2007;39:234\u20137.","journal-title":"J Extra Corpor Technol"},{"key":"891_CR22","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1097\/00007691-199308000-00001","volume":"15","author":"O Dagan","year":"1993","unstructured":"Dagan O, Klein J, Gruenwald C, Bohn D, Barker G, Koren G. Preliminary studies of the effects of extracorporeal membrane oxygenator on the disposition of common pediatric drugs. Ther Drug Monit. 1993;15:263\u20136.","journal-title":"Ther Drug Monit"},{"key":"891_CR23","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/1471-2253-12-29","volume":"12","author":"K Shekar","year":"2012","unstructured":"Shekar K, Roberts JA, Welch S, Buscher H, Rudham S, Burrows F, et al. ASAP ECMO: Antibiotic, Sedative and Analgesic Pharmacokinetics during Extracorporeal Membrane Oxygenation: a multi-centre study to optimise drug therapy during ECMO. BMC Anesthesiol. 2012;12:29.","journal-title":"BMC Anesthesiol"}],"container-title":["Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-015-0891-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13054-015-0891-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-015-0891-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-015-0891-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T03:17:47Z","timestamp":1691551067000},"score":1,"resource":{"primary":{"URL":"https:\/\/ccforum.biomedcentral.com\/articles\/10.1186\/s13054-015-0891-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["891"],"URL":"https:\/\/doi.org\/10.1186\/s13054-015-0891-z","relation":{},"ISSN":["1364-8535"],"issn-type":[{"value":"1364-8535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"20 August 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"164"}}